logo-loader
viewTissue Regenix Group PLC

Tissue Regenix reports significantly reduced losses

The regenerative medicine group also highlighted strong demand for its products in the first half of its current year despite disruption from the coronavirus pandemic

Tissue Regenix Group PLC - Tissue Regenix reports significantly reduced losses

Tissue Regenix Group PLC (LON:TRX) has reported significantly reduced losses in the first half of its current year as the company highlighted continued “strong” demand for its products despite market disruption caused by the coronavirus pandemic.

For the six months ended June 30, 2020, the regenerative medicine group reported an underlying EBITDA loss of £2.1mln, narrowed from a £3.6mln loss in the prior year, while revenues were maintained at the same level as a year ago at £6.1mln.

READ: Tissue Regenix secures first UK order for OrthoPure XT

The company also highlighted a reduction in its overhead cost base to £5.5mln from £7.1mln in the first half, adding that it has also secured additional distribution agreements in the period for its Matrix OI, DentalFix and AmnioWorks products to diversify its sales portfolio.

Tissue Regenix noted that its facility in San Antonio has also remained fully operational after implementing initiatives to reduce disruption caused by the pandemic.

Post-period, the firm said it has commenced phase one of a capacity expansion project at its US facility, as well as relocating its UK facility to Garforth in Leeds and signing a distribution agreement with a speciality supplier of orthopaedic and biologic products for its OrthoPure XT product.

"The first half of 2020 presented a number of challenges but, despite this, we achieved a number of milestones which will strengthen our market positioning going forward. Delivering revenues for the first half of the year comparable to the same 2019 period demonstrates that, despite [coronavirus] related market disruption, demand for our products remains strong”, Tissue Regenix interim chief executive Gareth Jones said in a statement.

Jones noted that the firm's recent £13.8mln fundraise in June has positioned the company well to capitalise on opportunities, while the launch of new products provided the firm with “greater access to new markets and opportunities in the future”.

“Due to the ongoing uncertainty around the [coronavirus] restrictions, it remains difficult for the Board to provide forward-looking guidance however, I am pleased with the progress that the Company continues to make and remain confident in the future prospects of the business", the CEO concluded.

Tissue Regenix shares were 8.4% lower at 0.32p in late-morning trading on Wednesday.

--Adds share price--

Quick facts: Tissue Regenix Group PLC

Price: 0.365 GBX

AIM:TRX
Market: AIM
Market Cap: £25.67 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 heads higher as markets welcome easing of restrictions

Headlines from the Proactive UK newsroom. The FTSE 100 rose 21 points to 6,957 as markets welcomed more easing of coronavirus lockdown measures across Europe despite some confusion in the UK. UK prime minister Boris Johnson, though, is being pressed for more clarity on the relaxation of UK...

on 11/5/20

2 min read